SBRT2015

SABR: Guidelines & evidence

SABR is the preferred treatment in patients with a peripheral early-stage NSCLC who are unfit for surgery, or who refuse it. [ESMO Clinical Practice Guidelines [Vansteenkiste J, Ann Oncol 2013; Guidelines of National Comprehensive Cancer Network [NCCN v3.2014 ]

Comparative effectiveness research suggests that survival is similar after either surgery or SABR for early-stage NSCLC [reviewed in Louie AV, Radiotherapy Oncol 2015]